



Preliminary
PROGRAMME

ICT 2025

29th International Congress
on Thrombosis
Porto, Portugal

6-8 November 2025
Sheraton Hotel



European and Mediterranean League
Against Thrombotic Diseases

emltd2025.com



Committees

Organising Committee

João Morais, PT | ICT 2025 Chairperson

Luciana Gonçalves, PT | ICT 2025 Chairperson

Daniel Caldeira, PT

Filipe Gonçalves, PT

Francisco Araújo, PT

Miguel Barbosa, PT

Silvia Monteiro, PT

Teresa Padró, ES

Scientific Committee (invited, to be confirmed)

Alexandros Tselepis, GR

Ana Bronic, CR

Bianca Rocca, IT

Bruna Gigante, SE

Cristina Gavina, PT

Diana Aguiar Sousa, PT

Eduardo Oliveira, PT

Gemma Vilhaur, SP

Georgia Kaiafa, GR

Gili Kennet, IL

Gregor Tratar, SI

Hrvoje Budincevic, HR

Ileana Desormais, FR

Ismail Elalamy, FR

Joana Liz Pimenta, PT

José Ramon Juanetey, ES

Juan Tamargo, ES

Lina Badimon, SP

Mojca Bozic, SI

Pedro Monteiro, PT

Rafaele De Caterina, IT

Ricardo Fontes Carvalho, PT

Rui Medeiros, PT

Sérgio Barroso, PT

Teresa Padró, ES

Ton Lisman, NL

Vittorio Pengo, IT

DAY 6 | MEETING ROOM A

14:00 | 14:30

Welcome address

14:30 | 16:00

Cancer Associated Thrombosis (CAT) - I

- Epidemiology
- Risk assessment models for VTE in cancer patients
- CAT and thrombocytopenia - Therapeutic challenge
- VTE and mortality in hematological malignancies
- Treatment of CAT: role of Factor XI inhibitors

16:00 | 16:30

Coffee break and poster exhibition

16:30 | 18:00

Thrombophilias, genetic disorders

- Update on inherited thrombophilias
- Acquired thrombophilias: the other side of the spectrum
- Coagulation and fertility: the role of thrombophilia
- Can DOACs play a role in inherited thrombophilia?
- Thrombophilia testing: from phenotype to genotype

18:00 | 18:30

Moderated Posters

DAY 6 | MEETING ROOM B

14:30 | 16:00

Mechanisms of thrombosis

- Visceral adiposity and increased thrombotic risk. Is the next therapeutic target
- Platelets in thrombosis and inflammation following trauma injuries
- Complement and coagulation. Strangers or partners in crime?
- Innate Immunity and neutrophil's role in atherothrombosis
- Lupus Anticoagulant: a puzzling laboratory test

16:00 | 16:30

Coffee break and poster exhibition

16:30 | 18:00

From lytics up to mechanical thrombectomy

- Mechanical thrombectomy vs catheter-directed thrombolysis for venous thromboembolism
- Modern treatment of pulmonary embolism in high risk patients
- Thrombolysis in acute ischemic stroke. An update
- Mechanical thrombectomy with or without lytics in acute ischemic stroke
- Composition of stroke thrombi

18:00 | 18:30

Moderated Posters

DAY 7 | MEETING ROOM A

09:00 | 10:00

Moderated posters

10:00 | 11:00

Joint Session EMLTD - Portuguese Association of Thrombosis and Haemostasis

Thrombotic diseases in children and young adults

- Pediatric thrombosis: Why, when
- Thrombosis in pediatric ICU patients
- Use of DOACs in pediatric patients
- Emergent strategies for thromboprophylaxis in children with cancer

11:00 | 11:30

Coffee break and poster exhibition

11:30 | 13:00

Joint Session EMLTD - Portuguese Association of Thrombosis and Haemostasis

Women, hormones and pregnancy

- Thrombosis in pregnancy: mechanisms and underlying risk factors
- Thrombosis in pregnancy: who should be on prophylaxis
- Thrombophilia testing in the obstetric setting
- Anticoagulation therapy in pregnancy. Managing risks
- Hormone therapy and thrombosis

13:00 | 14:00

Lunch time and sponsored sessions

DAY 7 | MEETING ROOM A

14:00 | 14:30

Keynote lecture: Unrolling the link on haemostasis, ageing and longevity

14:30 | 16:00

Cancer associated thrombosis (CAT) - II

- Endothelial dysfunction in cancer
- Approach to tumoral thrombosis
- CAT and immune checkpoint inhibitors: update
- Genetic markers of CAT
- Thrombotic risk versus haemorrhagic risk - strategies for decision

16:00 | 16:30

Coffee break and poster exhibition

16:30 | 17:30

Thrombotic risk in platelet disorders

- Immune thrombocytopenic purpura
- Rapid determination of ADAMTS13 – implication for the prompt diagnosis of TTP
- Treatment options of immune and congenital TTP
- What is DIC? Revised definitions/epidemiology and global burden of DIC

17:30 | 18:30

**Challenges in our daily clinical practice
Case based session**

18:30

EMLDT - General Assembly

DAY 7 | MEETING ROOM B

09:00 | 10:00

Meet the scientist **What I'm doing on my research**

10:00 | 11:00

Laboratory monitoring of haemostasis

- Inter-laboratory comparability of anti-Xa for measuring blood concentrations of oral anti-Xa inhibitors
- Global coagulation assays: is there a role in thrombosis risk evaluation
- Thrombin generation assay: from research to clinical use
- D-dimer assay: over-testing in VTE?

11:00 | 11:30

Coffee break and poster exhibition

11:30 | 13:00

Bleeding and hemorrhagic disorders

- Anemia and bleeding issues in women
- Novel treatments of bleeding disorders-are we increasing the risk of thrombosis?
- How to resume anticoagulants after an episode of severe bleeding
- Antithrombotic therapy in patients at high bleeding risk
- Antithrombotic treatment in patients with haematological diseases

13:00 | 14:00

Lunch time and sponsored sessions

DAY 7 | MEETING ROOM B

14:00 | 14:30

Keynote lecture: Cancer-associated thrombosis: pathophysiology complexity

14:30 | 16:00

News on antithrombotic therapy - I

- Factor XI inhibitors – premises, promises and challenges
- Intravenous antiplatelet drugs
- Stopping anticoagulation at the end of life
- Perioperative management of anticoagulant and antiplatelet therapy
- Novel strategies for anticoagulant reversal

16:00 | 16:30

Coffee break and poster exhibition

16:30 | 17:30

Atrial fibrillation a good model to test antithrombotic strategies

- How to assess thromboembolic risk beyond classical risk scores?
- Role of DOACs in patients with asymptomatic subclinical AF detected by device
- Antithrombotic treatment in acute coronary syndromes with coexisting atrialfibrillation
- How to organize an integrative clinical patient care pathway

17:30 | 18:00

Controversy: Factor XI inhibitors will replace DOACs in the near future

Pros and Cons

DAY 8 | MEETING ROOM A

09:00 | 10:00

Advances in cerebral venous thrombosis

10:00 | 11:00

DVT and pulmonary embolism

- Diagnosis and treatment of splanchnic vein thrombosis
- Prolonged treatment after VTE – which drugs to which patients?
- Anticoagulants for thrombosis of unusual sites- to DO(AC) or not to DO(AC)
- Thrombosis in multiple myeloma patients (use of PRISM SCORE)

11:00 | 11:30

Coffee break and poster exhibition

11:30 | 13:00

Joint Session EMLTD - Portuguese Society of Cardiology

Issues in Thrombocardiology

- Which is the optimal duration of dual antiplatelet therapy after ACS
- Is there still room for oral anticoagulants after ESUS in sinus rhythm?
- Antithrombotic management after non-coronary interventions
- Prosthetic heart valves. What changed in terms of thrombotic risk?

13:00 | 14:00

Lunch time and sponsored sessions

DAY 8 | MEETING ROOM A

14:00 | 14:30

Keynote lecture: Obesity, inflammation and thrombosis

14:30 | 16:00

News on antithrombotic therapy - II

- Novel antiplatelet and anticoagulant drugs under clinical development
- Which is the role of factor XI inhibitors? Insights from the clinical trials
- Bridging therapy in perioperative settings – Guidelines and practical approaches
- Bentracimab significantly restored platelet function in patients taking Ticagrelor and undergoing urgent surgery
- Antithrombotic strategies for patients with peripheral artery disease

16:00

Closing Session and Awards

DAY 8 | MEETING ROOM B

10:00 | 11:00

Immunothrombosis: molecular aspects and perspectives for therapy

- Modulating inflammatory response as therapeutic target in thrombosis
- Trauma and sepsis induced coagulopathy
- How to balance bleeding and thrombosis in patients under ECMO

11:00 | 11:30

Coffee break and poster exhibition

11:30 | 13:00

Topics to think, topics to react

- Antiphospholipid syndrome. A continuous challenge to the clinicians
- The role of NETs in Atherothrombosis
- Thrombocytopenia in patients with cancer-related VTE
- Haemostasis in progression of kidney disease

13:00 | 14:00

Lunch time and sponsored sessions

DAY 8 | MEETING ROOM B

14:00 | 14:30

Keynote lecture: Virus, vaccines and haemostasis: looking through the evidence

14:30 | 16:00

The role of Artificial Intelligence (AI) and machine learning

- AI as a tool to Improve diagnosis of venous thromboembolism
- Application of AI in the stroke unit
- AI in atrial fibrillation: from early detection to precision therapy
- AI applied to the diagnosis of coronary artery disease